The Effectiveness of Low-dose 161Tb-PSMA Treatment for Metastatic Castration-resistant Prostate Cancer
A 60-year-old man with metastatic castration-resistant prostate cancer (mCRPC), previously treated with antiandrogen therapy, experienced continued PSA rise and disease progression. He subsequently received 2 cycles of low-dose 161 Tb-PSMA radioligand therapy (RLT) with doses of 0.96 and 1.11 GBq, respectively. The follow-up results showed that the PSA of the patient decreased, the uptake of the lesions on 68 Ga-PSMA PET/CT reduced, and the symptoms of urinary retention were relieved. No acute toxicity or adverse reactions were observed.
Authors
- Fucen Liu
- Xia Yang (ORCID: https://orcid.org/0000-0003-0213-3061)
- Zhengguo Chen (ORCID: https://orcid.org/0000-0002-0607-0347)
- Zhaohui Zhu (ORCID: https://orcid.org/0000-0001-9931-850X)
- Liming Xiao (ORCID: https://orcid.org/0000-0002-8397-8682)
Institutions
- University of Electronic Science and Technology of China (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- China Academy of Engineering Physics (CN)
- Chinese Academy of Engineering (CN)
- Mianyang Central Hospital (CN)
Publication Details
- Journal
- Clinical Nuclear Medicine
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1097/rlu.0000000000006241
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00